Reckitt Benckiser Group PLC reported Q1 2026 like-for-like (LFL) net revenue growth of 1.3% for Core Reckitt, with Emerging Markets delivering +7.6% growth partially offset by a -4.2% decline in Europe and -0.9% decline in North America. Group IFRS net revenue declined -11.8% year-on-year to £3,247m, reflecting both foreign exchange headwinds and the prior-year contribution from the Essential Home business, which was divested on 31 December 2025. The company maintained its FY 2026 LFL net revenue guidance of +4% to +5% for Core Reckitt, with sequential growth expected as the cold and flu season resets and new product innovations launch including Mucinex 12hr Cold and Fever in North America in June 2026.